Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 10/20 | 0.32 |
| ▸ | CNR1 | P21554 | 6/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796539 | 0.95 | CYP2C9 (0.34) | CYP2C9MAPTESR2ALDH1A1LMNA | |
| SCHEMBL19796601 | 0.92 | TSHR (0.38) | CYP2C9MAPTESR2ALDH1A1LMNA | |
| SCHEMBL19796591 | 0.92 | TSHR (0.36) | CYP2C9MAPTESR2ALDH1A1LMNA | |
| SCHEMBL19796504 | 0.92 | CYP2C9 (0.35) | CYP2C9MAPTESR2ALDH1A1LMNA | |
| SCHEMBL19796229 | 0.92 | CYP2C9 (0.41) | CYP2C9MAPTESR2ALDH1A1LMNA | |
| SCHEMBL19797762 | 0.90 | CYP2C9 (0.35) | CYP2C9MAPTESR2ALDH1A1LMNA | |
| SCHEMBL19796706 | 0.90 | FFAR4 (0.34) | CYP2C9MAPTALDH1A1LMNACNR2 | |
| SCHEMBL19796991 | 0.88 | FFAR4 (0.34) | CYP2C9 | |
| SCHEMBL19796550 | 0.88 | TSHR (0.38) | CYP2C9MAPTESR2ALDH1A1LMNA | |
| SCHEMBL19796577 | 0.87 | FFAR4 (0.33) | CYP2C9CNR2CNR1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | CYP2C9 4202/4885MAPT 2308/4885ESR2 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.